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BACKGROUND: The relationship between cytokines and 
responses to peginterferon α-2a treatment in chronic hepatitis B 
patients has not yet been fully elucidated. We analyzed the serum 
levels of interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 
vascular endothelial growth factor, interferon-γ, tumor necrosis 
factor-α, monocyte chemotactic protein-1 (MCP1) and epidermal 
growth factor during the treatment with peginterferon α-2a. 
METHODS: Ninety-three serum samples from 20 chronic 
hepatitis B patients were collected before, during and after 48 
weeks of peginterferon therapy and were assayed for 12 cytokines. 
The patients were categorized as either virologic responders 
(VRs) or non-responders (NRs) according to their HBV DNA 
levels taken at 6th month during treatment. The Evidence 
Investigator (Randox, Antrim, UK), a protein chip analyzer, was 
used to quantify cytokines. 
RESULTS:  Among the 12 cytokines, the levels of MCP1 were 
increased and the levels of IL-4 were decreased during the 
treatment in VRs. However these cytokines were not significantly 
changed in NRs in the treatment phases. Area under the receiver 
operating characteristic curve (AUROC) value of HBV DNA 
measured before the treatment was 0.81 in predicting VRs, and 
that of the baseline MCP1 was 0.76. IL-6 levels at 3rd and 6th 
months during the treatment also showed AUROC values 0.85 
and 0.78 respectively in predicting sustained VRs.
CONCLUSION: Serum cytokine levels reflect the pathological 
differences of individual treatment phases and could also be 
useful in monitoring responses to peginterferon treatment in 
chronic hepatitis B patients.
(Hepatobiliary Pancreat Dis Int 2012;11:499-506)
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Introduction
Hepatitis  B  virus  (HBV)  is  a  common  etiologic agent  of  chronic  hepatitis.  HBV  is  thought not  to  be  cytolytic,  but  rather  HBV  infection 
induces  a  host  immunoreaction  against  its  viral 
products.  In  this  process,  cytokines  are  produced  by 
various  types  of  immune  cells  including  lymphocytes, 
macrophages, natural killer cells and dendritic cells, and 
these  cells  play  crucial  roles  in  the  course  of  chronic 
hepatitis B (CHB).[1, 2]
Inflammation  in  HBV-infected  hepatocytes  is 
caused  by  cytokines,  such  as  interferon-γ  (IFN-γ)  and 
tumor necrosis factor-α (TNF-α),[3] and these molecules 
also  trigger  elimination  of  the  virus.  Cytokines  such 
as  transforming  growth  factor-β  (TGF-β)  promote 
fibrosis of the liver,[4, 5] and hepatocarcinogenesis is also 
associated  with  abnormal  immune  responses  initiated 
by  various  types  of  cytokines  including  TGF-β  and 
interleukin (IL)-10.[6-8]  In a recent study,[9]  IL-6  limited 
adaptive immune responses and protected HBV-infected 
hepatocytes  from  death.  Another  study[10]  reported 
that increased IL-6 expression was associated with liver 
dysfunction after HBV infection. 




TGF-β  levels were  also higher  in CHB patients  than  in 
controls, whereas IFN-γ level was lower in patients than 
in  controls  in  another  study.[12]  Hepatic  flares  in  CHB 
patients were  also  associated with high  serum  levels of 
IFN-γ inducible chemokines such as chemokine (C-X-C 
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with  treatment  responses  to  drugs  in  CHB  has  rarely 
been reported.[14]
In  the  present  study  we  analyzed  serum  levels  of 
cytokines  in  CHB  patients  treated  with  peginterferon 
α-2a  in  their  treatment  phases  and  responses  to  the 
therapy.  Epidermal  growth  factor  (EGF),  IL-1α,  IL-
1β,  IL-2,  IL-4,  IL-6,  IL-8,  IL-10,  INF-γ,  monocyte 
chemotactic  protein-1  (MCP1),  TNF-α,  and  vascular 
endothelial  growth  factor  (VEGF) were  simultaneously 
assayed  in  specimens  obtained  from  the CHB patients. 




Altogether  93  serum  samples  were  prospectively 
collected with written informed consents from 20 CHB 
patients treated with peginterferon α-2a between January 




with  persistent  elevation  of  alanine  aminotransferase 
(ALT).[15]  The patients  showed  serum HBV DNA  levels 
greater  than  20 000  IU/mL  before  initiation  of  the 
therapy,  and were  treated with 180 μg of peginterferon 
α-2a  per week  for  48 weeks.  From  each patient,  one  or 
more samples were drawn at the following time points: 
before  peginterferon  therapy,  during  peginterferon 
therapy  (at  3rd  and  6th months  after  initiation  of  the 
therapy), and at 6th and 12th months after the therapy.
The  patients were  classified  as  virologic  responders 
(VRs)  when  serum  HBV  DNA  levels  at  6th  month 
after  initiation  of  the  therapy  were  decreased  to  less 
than  2000  IU/mL,[15-18]  and  the  other  patients  were 
classified  as  virologic  non-responders  (NRs).  The  VRs 
were subdivided into the sustained virologic responders 
(SVRs)  when  virologic  breakthrough  (increase  in 
serum HBV DNA by >1 log10 [10-fold] above nadir after 
achieving virologic response) was not observed until 12 
months off-treatment. This  study was  approved by  the 
Institutional  Review  Board  of  Severance  Hospital  and 
conducted  according  to  the  ethical  principles  of  the 
Declaration of Helsinki.
Measurement of cytokine levels 
All  serum  samples  were  separated  within  2  hours 
after  taking venous blood samples and stored at  -70 ℃ 
until use. A protein chip analyzer, Evidence Investigator 
and  Cytokine  Array  I  reagents  (Randox,  Antrim,  UK) 
were used  to measure 12  cytokines  including  IL-1α,  IL-
1β,  IL-2,  IL-4,  IL-6,  IL-8,  IL-10,  VEGF,  INF-γ,  TNF-α, 
MCP1  and  EGF.  The  assay  was  carried  out  according 
to  the  manufacturer's  instructions.  Frozen  serum 
specimens and the reagent carrier comprising 9 protein 











luminol  and  peroxidase was  added  to  each well  of  the 
chips and then after 2 minutes the carrier was inserted 
into  the  Evidence  Investigator  analyzer.  A  charge-
coupled  device  camera  detected  the  chip  signals  and 
saved  images  in  the  computer.  The  computer  program 




by  Cobas  AmpliPrep/Cobas  TaqMan  HBV  test  v2.0 
(Roche Molecular Systems, Inc., Pleasanton, CA., USA). 
Aspartate  aminotransferase  (AST)  and ALT  levels were 
measured  by  a  Hitachi  7600  DDP  modular  chemistry 
analyzer  (Hitachi  High-Technologies  Co.,  Tokyo, 
Japan).  Each  assay  was  performed  according  to  the 
manufacturer's instructions.
Statistical analysis
Statistical  analyses  were  made  using  Analyse-
it  Method  Evaluation  Edition  software  version  2.26 
(Analyse-it  Software  Ltd.,  City  West  Business  Park, 
Leeds,  UK).  Continuous  variables  between  the  two 
groups were compared using the Mann-Whitney U test. 
Multiple comparisons of continuous variables including 
levels  of  cytokines  among  the  patient  subgroups  and 
among  the  treatment  phases  were  performed  using 
the  Kruskal-Wallis  test  with  Bonferroni  correction  to 
compensate  for  alpha-statistical  errors.  Friedman's  test 
was also carried out  to compare cytokine  levels among 
the paired group. Categorical variables between the two 
groups  were  analyzed  for  the  difference  in  proportion 
by Fisher's exact test. Area under the receiver operating 
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characteristic  curves  (AUROCs)  of  the  cytokines  and 
HBV  DNA  were  calculated  to  assess  their  predictive 
values  for  virologic  responses.  P  values  less  than  0.05 
were considered as statistically significant.
Results
Characteristics of the CHB patients
Characteristics of  the patients are  summarized  in Table 
1. Age and male proportions were not different between 
the  VRs  (n=11)  and  NRs  (n=9).  Serum  AST  and  ALT 
levels  were  not  different  between  the  VRs  and  NRs 





therapy,  and  five  (45.5%)  showed  recurrence  of  active 
chronic  hepatitis  at  6  to  12  months  after  the  therapy, 
thus, six (54.5%) patients were classified into SVRs.
Serum levels of cytokines according to treatment 
phases and responses to the therapy 
Serum  levels  of  12  cytokines  in  the  phases  of 
peginterferon  therapy  in  the  VR  and  NR  groups  are 
summarized  in  Table  2.  The  levels  of  all  cytokines 
except for EGF, IFN-γ, IL-1α, IL-4, IL-6, IL-8, and MCP1 
were  not  different  among  the  groups  according  to  the 
responses to the therapy. The levels of MCP1 were higher 
during  the  therapy  than  before  the  therapy  at  3rd  and 
6th months  in  the  VR  group  (P=0.0371  at  3rd month 
and P=0.0011 at 6th month) (Fig. 1), whereas IL-4 levels 
were  lower  during  the  therapy  than before  the  therapy 
at 3rd and 6th months in the same group (P=0.0037 at 
3rd  month  and  P=0.0133  at  6th  month)(Fig.  1).  IL-6 
levels were  also  higher  during  the  therapy  than  before 
the  therapy  (P=0.0159  at  3rd  month  and  P=0.0174  at 
6th  month).  On  the  other  hand,  levels  of  those  three 
cytokines  were  not  significantly  changed  according  to 
the phases of the therapy in the NR group. In addition, 
MCP1  levels  were  also  higher  in  the  VRs  than  in  the 
NRs  during  and  after  the  therapy  (P<0.05),  and  EGF 
levels  were  decreased  at  3rd  month  in  the  VR  group 
during  the  therapy  compared  with  those  before  the 
therapy (P=0.0080).
Correlation between the serum levels of HBV DNA 
and cytokines 
Serum HBV DNA levels were weakly correlated with 
the  serum  levels  of  EGF  (r=0.33,  95% CI,  0.13  to  0.50, 
P=0.0016), IL-4 (r=0.31; 95% CI, 0.11 to 0.49; P=0.0025), 





-0.55  to  -0.20; P=0.0002),  and  IFN-γ  (r=-0.26;  95% CI, 






Parameters Virologic responders (n=11) Virologic non-responders (n=9) P value
Age (yr)   32.0 (26.3-36.0)   32.0 (26.0-35.0)    0.6556
Gender (n of male, %)     5 (45.5)     4 (44.4)    1.0000
Recurrence after Tx (n, %)     5 (45.5)     -    -
HBeAg seroconversion during or after Tx (n, %)     4 (36.4)     0    0.1362
AST (IU/L)
  Before Tx 120.0 (75.5-205.7)   83.5 (69.5-125.2)    0.3950
  During Tx*   33.0 (29.3-40.3)   59.0 (34.3-85.0)    0.0105
  After Tx#   25.0 (20.7-37.7)   45.0 (29.0-98.3)    0.0237
ALT (IU/L)
  Before Tx 143.0 (73.0-212.8) 170.5 (117.8-233.8)    0.5448
  During Tx*   30.0 (24.7-50.3)   67.0 (43.5-122.5)    0.0013
  After Tx#   27.0 (19.7-48.0)   69.0 (29.0-148.0)    0.0294
Serum HBV DNA (IU/mL)
  Before Tx     2.15×107 (7.72×105-6.94×107)   >1.70×108 (7.33×107->1.70×108)    0.0259
  During Tx*     1.74×102 (1.00×101-1.22×103)      9.01×106 (1.13×106-4.59×107) <0.0001
  After Tx#     1.94×103 (2.81×102-3.06×104)      2.75×107 (4.64×104-7.60×107)    0.0091
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Predictive values of cytokines and HBV DNA
Diagnostic  performances  of  HBV  DNA  and  some 
cytokines  are  summarized  in  Table  3.  The  AUROC 
value  of  serum  HBV  DNA  levels  measured  before 
peginterferon therapy was 0.81 (P=0.0017) in predicting 
VR  (n=11)  (Fig.  2A),  and  the  lower baseline HBV DNA 
level  was  related  to  the  higher  probability  of  VR.  The 
sensitivity and specificity of baseline HBV DNA levels in 
predicting VR were 72.7% and 87.5%, respectively, when 
the  cutoff  DNA  level  was  7.33×107  IU/mL.  Meanwhile, 
the  AUROC  value  of  baseline  MCP1  levels  was  0.76 
(P=0.0230) in detecting VR (n=11), and the higher MCP1 
level  was  related  to  VR.  The  sensitivity  and  specificity 
of  the baseline MCP1  level  in discriminating VRs  from 
NRs were 81.8% and 75.0%, respectively, with the cutoff 
value  of  213.9  pg/mL.  The AUROC  values  for  all  other 
cytokines  quantified  in  the  samples  before  the  therapy 
were not statistically significant in predicting VR.
In  addition,  the AUROC value of HBV DNA  levels, 
which was measured at 3rd month during the treatment 
was 0.85 (P=0.0001) in predicting SVR (n=6) (Fig. 2B), 
and  the  sensitivity  and  specificity  of  HBV DNA  levels 
at that time point were 100.0% and 61.5%, respectively 
(cutoff,  3.28×105  IU/mL).  The  AUROC  values  of  IL-6 
and IL-8 determined at 3rd month during the treatment 
were  0.85  (P=0.0001)  and  0.81  (P=0.0020)  respectively 
in  predicting  SVR,  and  the  higher  IL-6  and  IL-8 





6th  month  during  the  treatment  was  0.92  (P<0.0001) 
in predicting SVR, and the sensitivity and specificity of 
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cytokines  during  the  treatment  were  also  significantly 
associated with VR and SVR (Table 3).
Discussion
Liver  damage  after HBV  infection  is mediated  by  host 
immune  responses.  Acquired  and  innate  immunity  is 
thought  to  be  related  to  the  pathogenesis  of  CHB.  In 
this study, we analyzed the serum levels of 12 cytokines 
in  CHB  patients  to  evaluate  the  patterns  of  changes 
in  cytokines  according  to  the  treatment  phases  and 
responses to peginterferon α-2a, which is a widely used 
therapeutic  agent  for  the  treatment  of  CHB.  In  our 
study, the serum levels of MCP1, EGF, IFN-γ, IL-4, and 








Marker Measured time Target of prediction AUROC P value Cutoff * Sensitivity (%) Specificity (%)
HBV DNA Before Tx VR 0.81    0.0017 <7.33×107 IU/mL   72.7 87.5
MCP1 Before Tx VR 0.76    0.0230 >213.9 pg/mL   81.8 75.0
HBV DNA 3 mon during Tx SVR 0.85    0.0001 <3.28×105 IU/mL 100.0 61.5
IL-6 3 mon during Tx SVR 0.85    0.0001 >1.05 pg/mL 100.0 69.2
IL-8 3 mon during Tx SVR 0.81    0.0020 >18.55 pg/mL   76.9 83.3
HBV DNA 6 mon during Tx SVR 0.92 <0.0001 <1.18×103 IU/mL 100.0 76.9
IL-6 6 mon during Tx SVR 0.78    0.0058 >1.09 pg/mL 100.0 69.2
IL-6 increase# 6 mon-baseline VR 0.76    0.0351 >0.34 pg/mL   77.8 83.3
IFN-γ increase# 6 mon-baseline SVR 0.80    0.0098 <1.15 pg/mL 100.0 54.5
MCP1 increase# 6 mon-baseline SVR 0.77    0.0161 >102.0 pg/mL 100.0 63.6
IL-8 decrease# 3 mon-6 mon VR 0.76    0.0339 <17.55 pg/mL 100.0 57.1
EGF increase# 6 mon-3 mon VR 0.83    0.0020 >5.23 pg/mL   90.0 71.4
EGF increase# 6 mon-3 mon SVR 0.73    0.0451 >5.78 pg/mL 100.0 53.8
MCP1 increase# 6 mon-3 mon SVR 0.79    0.0051 >2.2 pg/mL 100.0 69.2
IL-4 decrease# Baseline-3 mon SVR 0.78    0.0307 >2.09 pg/mL   80.0 90.9
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the  levels  of  those  cytokines  during  each  treatment 
phase may  reflect  the  immunological  status of patients 
undergoing  peginterferon  therapy.  It  is  plausible  that 
the  host's  immune  responses  can  be  influenced  by  the 
administration  of  peginterferon  since  the  drug  has  a 
dual mode of action which acts not only as an antiviral 
agent but also as a regulator of the immune system.
In  our  study,  MCP1  was  significantly  increased 
during  the  therapy  (362.8  pg/mL  at  3rd  month  and 
395.0 pg/mL at  6th month)  compared with  that before 
therapy  (260.4  pg/mL)  in  VRs  but  not  in  NRs.  This 
would  imply  that  serum MCP1  levels  reflect  treatment 
phase  and  response  to  the  agent  in  CHB  patients.  A 
previous  study[19]  suggested  that  MCP1  plays  an  anti-
inflammatory  role  in  T  cell-mediated  hepatitis  by 
inhibiting  T  cell-derived  IL-4  production  through 
direct  stimulation  of  its  specific  receptor  chemokine 
(C-C motif) receptor 2 (CCR2). In our study, the serum 
levels  of MCP1 were  increased,  but  those  of  IL-4 were 
decreased  during  the  treatment  in  the  VR  group.  In 
addition,  the  serum  MCP1  level  was  also  increased 
during the treatment of patients with chronic hepatitis C 
by using IFN α-2b plus ribavirin, but in contrast to our 
study,  the  increase  of  MCP1  levels  in  non-responders 
was  significant.[20]  This  discrepancy  may  be  attributed 
to the difference of host immune responses to different 
viruses. MCP1, called as chemokine (C-C motif) ligand 
2  (CCL2),  small  inducible  cytokine  A2  (SCYA2),  and 
monocyte chemotactic and activating factor (MCAF), is 
known  to  act  as  a  pro-inflammatory  molecule,  which 
plays a key role in the recruitment of monocytes to the 
site  of  infection.  In  a  previous  study,[21]  the  2518G>A 
polymorphism  of  the  MCP1  gene  was  reported  to  be 
associated  with  whether  HBV  infected  individuals 








of  peginterferon  therapy  in  CHB  patients.  Because 
MCP1  levels  before  treatment  in  our  study  showed  an 
AUROC value of  0.76  in predicting  virologic  responses 
at 6th month during the treatment.
IL-6  is  an  endogenous  pyrogen  which  causes  fever 
as  an  inflammatory  response  in  the  body  and  acts  as 
pro-inflammatory  and  anti-inflammatory  cytokines. 
Its  level  was  elevated  during  the  therapy  in  the  VR 
group in our study. IL-6 was reported to suppress HBV 
replication  by  preventing  the  formation  of  genome-
containing nucleocapsids, which  is  similar  to  the effect 
of  interferons.[23]  In  contrast,  low  serum IL-6  level was 
reported  as  an  early  predictor  for  acute  exacerbation 
of  CHB.[24]  Therefore,  IL-6  also  could  be  a marker  for 
responses  to  peginterferon  therapy.  In  our  study  IL-6 
levels  measured  at  3rd  and  6th  months  during  the 
treatment  were  helpful  in  predicting  SVR  during  the 




EGF  was  decreased  during  the  early  phase  of 
peginterferon  therapy  compared  to  that  before  the 
therapy in our VR group. The finding indicates that the 
early  decrease  of  serum  EGF  level  during  the  therapy 
is  a  favorable  prognostic  factor  for  the  peginterferon 
treatment. A study[25]  reported that  the EGF-dependent 
upregulation  of  integrin  beta-1  chains  and  increased 
adhesion  to  extracellular  matrix  were  additional 
cytoprotective mechanisms of HBV infected hepatocytes. 
This study suggested that EGF can interfere with CD95-
mediated  apoptosis  and  the  action  of  cytotoxic  T-cells 
through  multiple  mechanisms  in  human  hepatocytes. 
However, EGF levels were increased in the later phase of 
peginterferon  therapy  (at 6th month during  treatment) 
compared  with  those  in  the  early  phase,  and  this 
increase was  also  related  to VRs  in  our  patients.  Thus, 
the dynamics of cytokines in CHB seems to be complex 
and needs further investigation.
Cytokines  are  key  molecules  in  the  complex 
signaling network of cell-mediated immunity. Analyses 
of  changes  in  cytokine  expression  patterns  during 
the  treatment  help  to  understand  the  pathogenesis 
of  CHB  and  predict  treatment  responses.  However,  a 
small  number  of  subjects  were  enrolled  in  this  study, 
and  thus  the  statistical  power  was  not  adequate  for 
assessment of the usefulness of cytokines in monitoring 
CHB  patients,  and  the  levels  of  some  cytokines  were 
changed  or  unchanged  according  to  statistical  analysis. 
Also,  VRs  to  the  treatment  of  CHB  patients  can  be 
influenced by various  factors  including viral  genotypes 
as well  as host's genetic  factors  such as HLA types and 
polymorphisms of many genes. Our data show changes 
in  the  levels  of  particular  cytokines  according  to 
treatment phases. Further  large-scale studies  to control 
various  confounding  factors  are necessary  to prove  the 
usefulness  of  cytokine  levels  as  predictive  factors  in 
CHB patients treated with peginterferon or other agents.
We  simultaneously  evaluated  12  cytokines  in 
the  sera  from  CHB  patients  in  order  to  detect  their 
expression  patterns  according  to  treatment  phases  and 
responses  to  therapy.  The  serum  levels  of  cytokines, 
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particularly MCP1,  EGF,  IL-4,  IL-6,  and  IL-8  reflected 
the  pathological  differences  of  the  treatment  phases. 
They could serve as indices for monitoring responses to 
peginterferon treatment in CHB patients. 
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